Pipeline

PRODUCT

INDICATION

STATUS

PC

Ph 1

Ph 2

Ph 3

Market

IGEM-F*

Ovarian, breast, lung

0%

IGEM-FR

Ovarian, breast, lung

0%

IGEM-Ch

Melanoma, TNBC

0%

IGEM-H

Breast, gastric

0%

*IGEM has an exclusive option to IGEM-F from King’s College London. IGEM-F is currently in a phase I trial in ovarian cancer sponsored by Cancer Research UK.